ERBB2 and metastasis: Previous studies have confirmed the high incidence of breast cancer brain metastasis, especially in HER2‐positive and triple‐negative subtypes, with rates as high as 30%–40% and a one‐year survival rate of only 20% after metastasis.30, 31, 32